Home > Oncology > BCC 2019 > St. Gallen Consensus > St. Gallen Consensus – Germ-line Mutations

St. Gallen Consensus – Germ-line Mutations

Conference
BCC 2019

Like 2 years ago, the panellists were asked to vote on the advisability of genetic testing for high risk (germ-line) mutations after counselling for several subtypes of patients with early breast cancer. In general, the panellists were more inclined to advise genetic testing compared to 2 years ago. There was absolute consensus (100% of the panellists voted “yes”) that all patients with a strong family history should be offered genetic testing. In addition, almost all panellists (96%) endorsed genetic testing in all patients who are younger than 35 years. A vast majority of the panellists (85%) was in favour of genetic testing in all patients with triple-negative breast cancer who are 60 years or younger at the time of diagnosis. However, only 39% of the panellists endorsed genetic testing in all patients with triple-negative breast cancer (regardless of their age); 33% of the panellists endorsed genetic testing in all patients with breast cancer who are younger than 50 years and...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on